Seres Therapeutics ( (MCRB) ) has shared an announcement.
On March 13, 2025, Seres Therapeutics reported its financial results for the fourth quarter and full year of 2024, alongside updates on its SER-155 program. The company highlighted significant progress with SER-155, which received Breakthrough Therapy designation from the FDA due to its potential to reduce bloodstream infections in allo-HSCT patients. The company plans to submit a draft study protocol to the FDA in Q2 2025, aiming to advance SER-155’s development and explore expansion into other patient populations. Market research indicates a strong commercial opportunity for SER-155, driven by the unmet need for effective prophylactic therapies against bloodstream infections.
More about Seres Therapeutics
Seres Therapeutics is a leading company in the live biotherapeutics industry, focusing on developing treatments for inflammatory and immune diseases. The company’s primary product, SER-155, is designed to prevent life-threatening bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplants (allo-HSCT).
YTD Price Performance: -17.50%
Average Trading Volume: 1,496,779
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $125.1M
For detailed information about MCRB stock, go to TipRanks’ Stock Analysis page.